<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933244</url>
  </required_header>
  <id_info>
    <org_study_id>H-2009-0055</org_study_id>
    <secondary_id>R01AG028739</secondary_id>
    <secondary_id>supplement</secondary_id>
    <nct_id>NCT00933244</nct_id>
  </id_info>
  <brief_title>Treatment of Vitamin D Insufficiency</brief_title>
  <official_title>Treatment of Vitamin D Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to answer the following questions: Does vitamin D increase
      calcium absorption, bone mass and muscle mass and function in women past menopause who have
      mildly low vitamin D levels? Do these benefits require prescription-strength vitamin D, or is
      an over the counter vitamin D dose enough?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is a major health problem in postmenopausal women. At age 50, half of women will
      suffer an osteoporotic fracture in their remaining lifetime, causing increased disability and
      mortality. Vitamin D deficiency, defined as a serum 25(OH)D &lt;15 ng/mL, contributes to
      osteoporosis via decreased calcium absorption (Ca·Ab), secondary hyperparathyroidism (HPT),
      increased bone resorption and decreased bone mineral density (BMD). Thus, experts agree that
      patients with vitamin D deficiency should receive vitamin D therapy.

      Vitamin D insufficiency (VDI) is a milder form of hypovitaminosis D defined as a 25(OH)D
      level between 15 and 30 ng/mL regardless of parathyroid hormone (PTH) status. Experts
      disagree on whether to treat VDI, as the clinical benefits of therapy are uncertain. Some
      experts insist the optimal 25(OH)D level is ≥30 ng/mL. By contrast, both the Food and
      Nutrition Board and NIH Evidence Report No. 158 state that insufficient evidence exists to
      declare the optimal serum 25(OH)D for bone health, despite review of ~170 studies.
      Consequently, the Food and Nutrition Board cannot determine a recommended daily allowance for
      vitamin D. Confusion over the optimal 25(OH)D level results, in part, because previous trials
      failed to recruit subjects based on initial 25(OH)D levels and/or failed to target or achieve
      25(OH)D levels ≥30 ng/mL. Moreover, secondary HPT, the proposed mechanism by which VDI causes
      bone loss, occurs in only 10% to 33% of people with VDI. As such, people with VDI and normal
      PTH might not experience clinical benefits from vitamin D therapy. VDI is widespread,
      affecting 26% to 39% of postmenopausal American women with and without osteoporosis.
      Therefore, determining the ideal 25(OH)D level for optimal calcium homeostasis and bone
      health is of utmost clinical and public health importance. Our overall goal, congruent with
      Healthy People 2010 objective 2-9, is to evaluate the effect of vitamin D therapy on the risk
      of osteoporosis in postmenopausal women with VDI, as reflected by changes in Ca·Ab, BMD and
      muscle fitness. Our second goal is to evaluate whether a high-dose vitamin D regimen, chosen
      to achieve and maintain a 25(OH)D level ≥30 ng/mL, is superior in its effects on study
      outcomes compared to a low-dose vitamin D regimen that can permit continued VDI.

      We will conduct a randomized, placebo-controlled double-blind trial of low-dose and high-dose
      vitamin D in postmenopausal women with vitamin D insufficiency in order to investigate the
      following aims:

        1. To evaluate the effect of vitamin D3 therapy on Ca·Ab in postmenopausal women less than
           or equal to 75 years old with VDI. Sub-aims include the investigation of subject
           variables influencing Ca·Ab and 25(OH)D levels at baseline and one month, the accuracy
           of oral isotope plasma levels for Ca·Ab measurement and the ability of a questionnaire
           to identify patients with low vitamin D status.

        2. To evaluate the effects of vitamin D3 therapy on the 12-month change in BMD and bone
           turnover in the same trial conducted for Aim 1. Sub-aims include the identification of
           subject variables significantly influencing change in BMD and an evaluation of the
           relationship between changes in Ca·Ab and changes in BMD.

        3. To evaluate the effect of vitamin D therapy on muscle mass and functional capacity in
           the same trial conducted for Aim 1. We will measure muscle mass by whole body bone
           densitometry and assess muscle function using the Timed Up and Go (TUG) Test and the
           modified Stanford Health Assessment Questionnaire (HAQ) score. Sub-aims include the
           identification of subject variables significantly influencing muscle outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal Calcium Absorption</measure>
    <time_frame>One Year</time_frame>
    <description>Percent of calcium absorbed in the intestinal tract within one day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>1 Year</time_frame>
    <description>Annualized percent change in bone mineral density at spine, hip, femoral neck, and body</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone Turnover</measure>
    <time_frame>0, 30, 60, 120, 365 days</time_frame>
    <description>C-telopeptide (pg/mL) was measured at baseline, 30 days, 60 days, 120 days, 365 days in the subset of subjects who arrived at all study visit fasting since midnight and had phlebotomy prior to 10 am. Data demonstrated outliers and was summarized using the median (25th, 75th interquartile range).</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle Function: One Year Change in Timed Up and Go Test, Five Sit-to-Stand Test</measure>
    <time_frame>1 Year</time_frame>
    <description>We summarized within-arm one-year changes in continuous muscle outcomes using the mean (95% confidence interval).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>High Dose Vitamin D3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Vitamin D3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Dose Vitamin D3</intervention_name>
    <description>Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.</description>
    <arm_group_label>High Dose Vitamin D3</arm_group_label>
    <other_name>Vitamin D</other_name>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Dose Vitamin D3</intervention_name>
    <description>White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.</description>
    <arm_group_label>Low Dose Vitamin D3</arm_group_label>
    <other_name>Vitamin D</other_name>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vitamin D insufficiency, defined as a serum 25(OH)D 16 to 25 ng/mL by high performance
             liquid chromotography assay

          -  Women ≥ 5 years past the date of last menses or bilateral oophorectomy, or ≥ 60 years
             old if they had prior hysterectomy without bilateral oophorectomy

          -  Total dietary and supplemental calcium intake &lt; 600 mg daily but ≤ 1,400 mg daily,
             based on a food frequency questionnaire

        Exclusion Criteria:

          -  Women &gt; 75 years old

          -  Hypercalcemia (serum calcium corrected for albumin &gt; 10.4 mg/dL)

          -  Nephrolithiasis by medical record or patient report

          -  Inflammatory bowel disease, malabsorption or chronic diarrhea

          -  Stage 3, 4 or 5 Chronic Kidney Disease based on the Modification of Renal Diet (MDRD)
             formula

          -  Use of bone-active medications within the past 6 months including bisphosphonates,
             estrogen compounds, calcitonin, teriparatide, oral corticosteroids and anticonvulsants

          -  Allergy or intolerance to orange juice

          -  Allergy or intolerance to sunscreen

          -  Prior adult clinical fragility fracture of the hip, spine or wrist or a T-score below
             -2.5 at the lumbar spine or femur
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Hansen, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Engelke JA, Shafer MM. Vitamin D insufficiency: disease or no disease? J Bone Miner Res. 2008 Jul;23(7):1052-60. doi: 10.1359/jbmr.080230.</citation>
    <PMID>18302509</PMID>
  </reference>
  <reference>
    <citation>Ramsubeik K, Keuler NS, Davis LA, Hansen KE. Factors associated with calcium absorption in postmenopausal women: a post hoc analysis of dual-isotope studies. J Acad Nutr Diet. 2014 May;114(5):761-7. doi: 10.1016/j.jand.2013.07.041. Epub 2013 Oct 24.</citation>
    <PMID>24209888</PMID>
  </reference>
  <results_reference>
    <citation>Nabak AC, Johnson RE, Keuler NS, Hansen KE. Can a questionnaire predict vitamin D status in postmenopausal women? Public Health Nutr. 2014 Apr;17(4):739-46. doi: 10.1017/S1368980013001973. Epub 2013 Jul 22.</citation>
    <PMID>23870503</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen KE, Johnson RE, Chambers KR, Johnson MG, Lemon CC, Vo TN, Marvdashti S. Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial. JAMA Intern Med. 2015 Oct;175(10):1612-21. doi: 10.1001/jamainternmed.2015.3874.</citation>
    <PMID>26237520</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <results_first_submitted>June 16, 2015</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2015</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Parathyroid Hormone</keyword>
  <keyword>Calcium Absorption</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Muscle Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Vitamin D</title>
          <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Vitamin D</title>
          <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects' baseline data is reported herein</population>
      <group_list>
        <group group_id="B1">
          <title>High Dose Vitamin D</title>
          <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Vitamin D</title>
          <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="76"/>
            <count group_id="B4" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="5"/>
                    <measurement group_id="B2" value="60" spread="6"/>
                    <measurement group_id="B3" value="61" spread="6"/>
                    <measurement group_id="B4" value="61" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intestinal Calcium Absorption</title>
        <description>Percent of calcium absorbed in the intestinal tract within one day</description>
        <time_frame>One Year</time_frame>
        <population>4% of subjects withdrew from the study. Additionally the calcium isotope dose was not recorded in 2 subjects and a urine sample was mishandled in a third. Thus, the number of participants analyzed is less than the number randomized into the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Intestinal Calcium Absorption</title>
          <description>Percent of calcium absorbed in the intestinal tract within one day</description>
          <population>4% of subjects withdrew from the study. Additionally the calcium isotope dose was not recorded in 2 subjects and a urine sample was mishandled in a third. Thus, the number of participants analyzed is less than the number randomized into the trial.</population>
          <units>Total Fractional Calcium Absorption</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" lower_limit="0.154" upper_limit="0.243"/>
                    <measurement group_id="O2" value="0.217" lower_limit="0.168" upper_limit="0.276"/>
                    <measurement group_id="O3" value="0.183" lower_limit="0.138" upper_limit="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" lower_limit="0.168" upper_limit="0.258"/>
                    <measurement group_id="O2" value="0.172" lower_limit="0.144" upper_limit="0.231"/>
                    <measurement group_id="O3" value="0.174" lower_limit="0.137" upper_limit="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density</title>
        <description>Annualized percent change in bone mineral density at spine, hip, femoral neck, and body</description>
        <time_frame>1 Year</time_frame>
        <population>Annual changes in bone mineral density were analyzed for subjects who completed the study. 9 subjects (4%) withdrew from the study, all for personal reasons. Thus, number of participants analyzed is 4% less than number of subjects randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>Annualized percent change in bone mineral density at spine, hip, femoral neck, and body</description>
          <population>Annual changes in bone mineral density were analyzed for subjects who completed the study. 9 subjects (4%) withdrew from the study, all for personal reasons. Thus, number of participants analyzed is 4% less than number of subjects randomized.</population>
          <units>Percent Change in Bone Mineral Density</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Annualized Percent Change in BMD at Spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.9" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2.1" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-1.7" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annualized Percent Change in Total Hip BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.3" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-1.2" upper_limit="0.2"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-1.9" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annualized Percent Change in Femoral Neck BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.3" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-2.3" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-2.0" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annualized Percent Change in Total Body BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.1" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-3.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1.6" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Bone Turnover</title>
        <description>C-telopeptide (pg/mL) was measured at baseline, 30 days, 60 days, 120 days, 365 days in the subset of subjects who arrived at all study visit fasting since midnight and had phlebotomy prior to 10 am. Data demonstrated outliers and was summarized using the median (25th, 75th interquartile range).</description>
        <time_frame>0, 30, 60, 120, 365 days</time_frame>
        <population>Bone turnover markers were analyzed in duplicate for the subset of subjects who arrived at all study visit fasting since midnight and had phlebotomy prior to 10 am.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover</title>
          <description>C-telopeptide (pg/mL) was measured at baseline, 30 days, 60 days, 120 days, 365 days in the subset of subjects who arrived at all study visit fasting since midnight and had phlebotomy prior to 10 am. Data demonstrated outliers and was summarized using the median (25th, 75th interquartile range).</description>
          <population>Bone turnover markers were analyzed in duplicate for the subset of subjects who arrived at all study visit fasting since midnight and had phlebotomy prior to 10 am.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-telopeptide (pg/mL) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="74" upper_limit="101"/>
                    <measurement group_id="O2" value="97" lower_limit="80" upper_limit="107"/>
                    <measurement group_id="O3" value="98" lower_limit="78" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-telopeptide (pg/mL) at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-5" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="-3" upper_limit="4"/>
                    <measurement group_id="O3" value="0" lower_limit="-6" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-telopeptide (pg/mL) at 60 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-3" upper_limit="6"/>
                    <measurement group_id="O2" value="-1" lower_limit="-5" upper_limit="2"/>
                    <measurement group_id="O3" value="-1" lower_limit="-5" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-telopeptide (pg/mL) at 120 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O2" value="-1" lower_limit="-5" upper_limit="2"/>
                    <measurement group_id="O3" value="-2" lower_limit="-5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-telopeptide (pg/mL) at 365 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O2" value="0" lower_limit="-4" upper_limit="5"/>
                    <measurement group_id="O3" value="0" lower_limit="-5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Muscle Function: One Year Change in Timed Up and Go Test, Five Sit-to-Stand Test</title>
        <description>We summarized within-arm one-year changes in continuous muscle outcomes using the mean (95% confidence interval).</description>
        <time_frame>1 Year</time_frame>
        <population>4% of subjects withdrew from the study and muscle tests were not conducted in four additional subjects who sustained injury or reported leg pain during a study visit. Thus the number analyzed is less than the number randomized into the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function: One Year Change in Timed Up and Go Test, Five Sit-to-Stand Test</title>
          <description>We summarized within-arm one-year changes in continuous muscle outcomes using the mean (95% confidence interval).</description>
          <population>4% of subjects withdrew from the study and muscle tests were not conducted in four additional subjects who sustained injury or reported leg pain during a study visit. Thus the number analyzed is less than the number randomized into the trial.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>One Year Change in Timed Up and Go Test (seconds)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" lower_limit="-0.66" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-0.44" lower_limit="-0.66" upper_limit="-0.22"/>
                    <measurement group_id="O3" value="-0.35" lower_limit="-0.70" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One Year Change in Five Sit-to-Stand Test (sec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" lower_limit="-1.44" upper_limit="-0.63"/>
                    <measurement group_id="O2" value="-0.98" lower_limit="-1.49" upper_limit="-0.47"/>
                    <measurement group_id="O3" value="-0.55" lower_limit="-1.02" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Vitamin D</title>
          <description>Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days.
High Dose Vitamin D3: Yellow gel-cap vitamin D3 at 50,000 International Units to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Vitamin D</title>
          <description>Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days.
Low Dose Vitamin D3: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 355 days
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days.
Placebo: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days.
Placebo: White gel-cap placebo pills to take orally, daily for 355 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ONCORE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ONCORE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="75"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune System</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and Infestation</sub_title>
                <counts group_id="E1" events="70" subjects_affected="43" subjects_at_risk="79"/>
                <counts group_id="E2" events="73" subjects_affected="42" subjects_at_risk="75"/>
                <counts group_id="E3" events="80" subjects_affected="37" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, procedural</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal, Connective Tissue</sub_title>
                <counts group_id="E1" events="83" subjects_affected="44" subjects_at_risk="79"/>
                <counts group_id="E2" events="98" subjects_affected="52" subjects_at_risk="75"/>
                <counts group_id="E3" events="102" subjects_affected="53" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm, Benign, Malignant</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, Peuperium, Perinatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive and Breast</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, Thoracic, Mediastinal</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and Subcutaneous Tissue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social Circumstances</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and Medical Procedures</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen E Hansen</name_or_title>
      <organization>University of Wisconsin - School of Medicine &amp; Public Health</organization>
      <phone>608-265-8162</phone>
      <email>keh@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

